|
|
Volumn 111, Issue 7, 2014, Pages 1310-1318
|
|
Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE;
ANTINEOPLASTIC AGENT;
CETUXIMAB;
DASATINIB;
MONOCLONAL ANTIBODY;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
RAS PROTEIN;
THIAZOLE DERIVATIVE;
VASCULOTROPIN A;
VEGFA PROTEIN, HUMAN;
ANIMAL;
ARTICLE;
CELL PROLIFERATION;
DNA REPLICATION;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG SCREENING;
FEMALE;
HUMAN;
METABOLISM;
MOUSE;
NEOVASCULARIZATION (PATHOLOGY);
NUDE MOUSE;
RADIATION DOSE FRACTIONATION;
RADIATION EXPOSURE;
SECRETION (PROCESS);
TUMOR CELL LINE;
TUMOR VOLUME;
ANIMALS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CELL LINE, TUMOR;
CELL PROLIFERATION;
DNA REPLICATION;
DOSE FRACTIONATION;
FEMALE;
HUMANS;
MICE;
MICE, NUDE;
NEOVASCULARIZATION, PATHOLOGIC;
PYRIMIDINES;
RAS PROTEINS;
SRC-FAMILY KINASES;
THIAZOLES;
TUMOR BURDEN;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
XENOGRAFT MODEL ANTITUMOR ASSAYS;
|
|
EID: 84910003860
PISSN: None
EISSN: 15321827
Source Type: Journal
DOI: 10.1038/bjc.2014.432 Document Type: Article |
|
Times cited : (18)
|
|
References (0)
|
